Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asano H, Ohashi H, Ichihara M, Kinoshita T, Murate T, Kobayashi M, Saito H, Hotta T (1994) Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 84:588–594
Backx B, Broeders L, Lowenberg B (1992) Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. Blood 80:1213–1217
Backx B, Broeders L, Touw I, Lowenberg B (1993) Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 7:75–79
Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131–133
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) Co-Operative Group (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199
Boudard D, Sordet O, Piselli S, Viallet A, Guyotat D, Campos L (2002) Increased caspase-3 activity in refractory anemias: lack of evidence for Fas pathway implication. Leukemia 16:2343–2345
Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarre MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327
Cazzola M, Barosi G, Berzuini C, Dacco M, Orlandi E, Stefanelli M, Ascari E (1982) Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol 50:55–62
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, Rolandi V, Biasiotto G, Drysdale J, Arosio P (2003) Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101:1996–2000
Chalevelakis G, Karaoulis S, Yalouris AG, Economopoulos T, Tountas N, Raptis S (1991) Globin chain synthesis in myelodysplastic syndromes. J Clin Pathol 44:134–138
Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M (2002) In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99:1594–1601
Di Raimondo F, Longo G, Cacciola E Jr, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R (1996) A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56:7–11
Dror Y (2003) The role of mitochondrial-mediated apoptosis in a myelodysplastic syndrome secondary to congenital deletion of the short arm of chromosome 4. Exp Hematol 31:211–217
Economopoulos T, Mellou S, Papageorgiou E, Pappa V, Kokkinou V, Stathopoulou E, Pappa M, Raptis S (1999) Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia 13:1009–1012
Garypidou V, Verrou E, Vakalopoulou S, Perifanis V, Tziomalos K, Venizelos I (2003) Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 123:958
Gattermann N (2004) Mitochondrial DNA mutations in the hematopoietic system. Leukemia 18:18–22
Gattermann N, Wulfert M, Junge B, Germing U, Haas R, Hofhaus G (2004) Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood 103:1499–1502
Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C (2000a) Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 108:724–728
Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000 b) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992
Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113–119
Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E (1993) Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Hematol 44:229–236
Hast R, Wallvik J, Folin A, Bernell P, Stenke L (2001) Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 25:13–18
Hellstrom-Lindberg E (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67–71
Hellstrom-Lindberg E, Birgegard G, Carlsson M, Cameskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I (1993) A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221–228
Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A (1997 a) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 21:415–425
Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Ost A, Greenberg P (1997b) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351
Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Cameskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68–75
Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B (2001) Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 112:714–726
Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Lofvenberg E, Oberg G, Porwit-Mac-Donald A, Radlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120:1037–1046
Higgs DR, Wood WG, Barton C, Weatherall DJ (1983) Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med 75:181–191
Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270
Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y (1994) Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 68:163–166
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 103:1070–1074
Koeffler HP, Cline MJ, Golde DW (1978) Erythropoiesis in preleukemia. Blood 51:1013–1019
Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P (1996) Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 95:368–371
Lintula R (1986) Red cell enzymes in myelodysplastic syndromes: a review. Scand J Haematol Suppl 45:56–59
List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364–3369
Mantovani L, Lentini G, Hentschel B, Wickramanayake PD, Loeffler M, Diehl V, Tesch H (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 109:367–375
Matthes TW, Meyer G, Samii K, Beris P (2000) Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 111:843–852
May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R (1985) The myelodysplastic syndrome: analysis of laboratory characteristics in relation to the FAB classification. Br J Haematol 59:311–319
Michalopoulou S, Micheva I, Kouraklis-Symeonidis A, Kakagianni T, Symeonidis A, Zoumbos NC (2004) Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state. Leuk Res 28:805–812
Negrin RS, Nagler A, Kobayashi Y, et al (1992) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood 78:36–43
Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL (1993) Treatment of the anemia of myelodysplatic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737–743
Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076–4081
Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellstrom-Lindberg E, Hast R, Jacobsen SE (2000) Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 96:2012–2021
Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96:3932–3938
Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT (1997) Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 99:625–631
Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A, Loew J, Marcus B, Khan Z, Chaney C, Showel J, Gregory S, Preisler H (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268–276
Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S, Preisler H (1996) A paradigm shift in myelodysplastic syndromes. Leukemia 10:1648–1652
Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez F, I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 84:1058–1064
Rigolin GM, Porta MD, Bigoni R, Cavazzini F, Ciccone M, Bardi A, Cuneo A, Castoldi G (2002) rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors’ response by fluorescence in situ hybridization on May-Grun-wald-Giemsa-stained bone marrow samples. Br J Haematol 119:652–659
Rodriguez JN, Dieguez JC, Muniz R, Martino ML, Femandez-Jurado A, Amian A, Canavate M, Prados D (1994) Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia: meta-analytic study [Spanish]. Sangre 39:435–439
Rose EH, Abels Rl, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831–837
Sanz GF, Sanz MA, Vallespì T, Cañizo MC, Torrabadella M, Garcia S, Irriguible D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395–408
Sawada K, Sato N, Notoya A, Tarumi T, Hirayama S, Takano H, Koizumi K, Yasukouchi T, Yamaguchi M, Koike T (1995) Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopu-lations of marrow CD34+ cells. Blood 85:194–202
Schmidt-Mende J, Tehranchi R, Forsblom AM, Joseph B, Christensson B, Fadeel B, Zhivotovsky B, Hellstrom-Lindberg E (2001) Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 15:742–751
Shin MG, Kajigaya S, Levin BC, Young NS (2003) Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 101:3118–3125
Sokol RJ, Hewitt S, Booker DJ (1989) Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 42:1088–1091
Stasi R, Brunetti M, Bussa S, Conforti M, Di Giulio C, Crescenzi A, Terzoli E, Vecchione A, Pagano A (1997a)
Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 3:733–739
Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A (1997 b) Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clin Lab Haematol 19:197–201
Stasi R, Pagano A, Terzoli E, Amadori S (1999) Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 105:141–148
Suarez L, Vidriales MB, Sanz G, Lopez A, Lopez-Berges MC, de Santiago M, Palomera L, Bernal T, Perez dEM, San Miguel JF, Orfao A (2004) Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34− bone marrow cell compartments from patients with myelodysplastic syndromes. Leukemia 18:1311–1313
Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, Hellstrom-Lindberg E (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101:1080–1086
Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N, Manioudaki E, Lazaridou A, Bakaloudi V, Protopappa M, Liapi D, Grouzi E, Parharidou A, Symeonidis A, Kokkini G, Laoutaris NP, Vaipoulos G, Anagnostopoulos NI, Christakis JI, Meletis J, Bourantas KL, Zoumbos NC, Yataganas X, Viniou NA, for The Greek MDS Study Group (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 118:174–180
Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, Rose EH, Dugan MH (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175–1179
Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocyte macrophage colony stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Bowen, D.T. (2006). Hematopoietic Growth Factors. In: Hematologic Malignancies: Myelodysplastic Syndromes. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30794-X_10
Download citation
DOI: https://doi.org/10.1007/3-540-30794-X_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-26188-9
Online ISBN: 978-3-540-30794-5
eBook Packages: MedicineMedicine (R0)